Skip to main content

Table 1 Outcomes for the Surgical Arm

From: SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449)

 

Surgical Arm

No Touch (n = 127)

n (%)

Conventional (n = 123)

n (%)

Odds Ratio, (95% Confidence Interval)

p-value*

Interaction**p-value

Primary Outcome:

Proportion of study SVG with complete occlusion or death from cardiovascular cause at 1 year

7 (5.5)

13 (10.6)

0.49 (0.19–1.28)

0.15

0.35

Proportion of study SVG with complete occlusionc

7 (6.9)

11 (10.3)

0.64 (0.24–1.73)

0.38

 

Death from cardiovascular cause

0 (0)

2 (1.6)

0.24

 

Secondary Outcomesc

 Proportion of study SVG with significantb stenosis at 1 year

1 (1.0)

5 (4.7)

0.20 (0.02–1.76)

0.12

0.96

 Proportion of study SVG with significantb stenosis or complete occlusion

8 (7.8)

16 (15.0)

0.48 (0.20–1.19)

0.11

0.72

 MACCEd

23 (18.1)

19 (15.4)

1.19 (0.64–2.19)a

0.59

0.87

Components of MACCE

 All-cause mortality

1 (0.8)

4 (3.3)

0.24 (0.03–2.14) a

0.20

 

 Non-fatal MI (MACCE)d

19 (15.0)

14 (11.4)

1.33 (0.66–2.67) a

0.43

 

 Repeat revascularization

2 (1.6)

4 (3.3)

0.47 (0.09–2.57) a

0.38

 

 Stroke

2 (1.6)

1 (0.8)

1.94 (0.18–21.4) a

0.59

 
  1. Abbreviations: MACCE major adverse cardiac and cerebrovascular events defined by all-cause mortality, non-fatal myocardial infarction, repeat revascularization, or stroke at 1 year
  2. Legend:
  3. *Test of significance between No-touch and Conventional, using the logistic regression model for the primary outcome or Fisher’s Exact tests with 0 cells or Cox Proportional hazards model for the MACCE and components of MACCE
  4. **Interaction was tested between surgical and pharmacological arm for each of the primary and secondary outcomes
  5. aHazard ratio
  6. bSignificant stenosis defined by 50–99% stenosis
  7. cNote, 102 patients with study SVGs in the No Touch group and 107 patients in the Conventional group underwent 1-year angiogram and therefore contributed to secondary angiographic outcomes
  8. d31/33 non-fatal MI (MACCE) events occurred between 0 and 31 days after surgery